To evaluate whether patients with rheumatoid arthritis who did not respond sufficiently to tocilizumab ( TCZ ) plus disease-modifying antirheumatic drug ( DMARD ) treatment by Week @ responded at later timepoints when continuing to take their original dose of TCZ .